Thrombophilia, clinical factors, and recurrent venous thrombotic events

JAMA

Volumn 293, Issue 19, 2005, Pages 2352-2361

  Christiansen, Sverre C ^a   Cannegieter, Suzanne C ^a   Koster, Ted ^a   Vandenbroucke, Jan P ^a   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HOMOCYSTEINE; ORAL CONTRACEPTIVE AGENT; BLOOD CLOTTING FACTOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 18644369163     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.19.2352     Document Type: Article

References (41)

1. Anderson FA Jr, Brownell-Wheeler H, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
2. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
3. Oger E; EPI-GETBP Study Group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2000;83:657-660.
4. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610-619.
5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C Nature. 1994;369:64-67.
6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
7. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
8. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaat FR. High levels of factor IX increase the risk of venous thrombosis. Blood, 2000;95:3678-3682.
9. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701.
10. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
11. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719-722.
12. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
13. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
14. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
15. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
16. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001;113:630-635.
17. Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628.
18. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
19. Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002;162:2357-2360.
20. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H; DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allelein the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost. 1999;81:684-689.
21. Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001;37:215-218.
22. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
23. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost. 1996;75:229-232.
24. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
25. Simioni P, Prandoni P, Lensing AWA, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.
26. Document on clinical validity. Available at: http://www.cdc.gov/genomics/ activities/files/print/VTE_ClinicalValidity.pdf. Accessibility verified April 18, 2005.
27. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
28. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost. 2003;1:28-32.
29. den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345:882-885.
30. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
31. Lensing AWA, Prins MH. Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis? Thromb Haemost. 1999;82:1564-1566.
32. Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity orvice versa? J Thromb Haemost. 2003;1:16-18.
33. van der Meer FJM, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1997;78:631-635.
34. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
35. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
36. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
37. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.
38. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-2563.
39. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost. 2004;2:2152-2155.
40. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955-960.
41. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation. 1983;67:901-906.